Redx Pharma plc Grant of Options (1506A)

TIDMREDX

RNS Number : 1506A

Redx Pharma plc

22 December 2017

REDX PHARMA PLC

("Redx" or "the Company")

Grant of Options

Alderley Park, December 22 2017- Redx Pharma (AIM:REDX), the drug discovery and development company, today announces that on 21 December 2017 options over 500,000 ordinary shares of 1p each in the share capital of the Company, were granted to Dominic Jackson, Chief Financial Officer, under Redx's Enterprise Management Incentive Scheme.

One-third of the options are exercisable at a price of 22p and will vest immediately, one-third are exercisable at a price of 33p and will vest on the 1 year anniversary of the grant, and one-third are exercisable at a price of 50p and will vest on the 2 year anniversary of the grant. None of these options will become exercisable until the second anniversary of grant.

In addition, options over 3,260,000 ordinary shares of 1p each in the share capital of the Company were granted to the management and staff of the Company, also under Redx's Enterprise Management Incentive Scheme. These options are exercisable at the same prices and on the same terms as above.

For further information, please contact:

 
Redx Pharma Plc                       T: +44 1625 
                                       469 918 
Iain Ross, Executive Chairman 
 
 Cantor Fitzgerald Europe (Nominated   T: +44 20 
  Advisor & Broker)                     7894 7000 
Phil Davies 
 
WG Partners LLP (Joint Broker)        T: +44 20 
                                       3705 9330 
Claes Spång/ Chris Lee/ David 
 Wilson 
 
FTI Consulting                        T: +44 20 
                                       3727 1000 
Simon Conway/Stephanie Cuthbert 
 

About Redx Pharma

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, Redx pursues targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, the Company is focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas Redx's aim is to develop drugs whose profile suggests they will be best in class, if not first in class.

 
 Notification of a Transaction pursuant to Article 
  19(1) of Regulation (EU) No. 596/2014 
----------------------------------------------------------------- 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ------------------------------------------------------------ 
 a.   Name                    Dominic Jackson 
---  ----------------------  ------------------------------------ 
 2    Reason for 
       notification 
---  ----------------------  ------------------------------------ 
 a.   Position/Status         Chief Financial Officer 
---  ----------------------  ------------------------------------ 
 b.   Initial notification/   Initial Notification 
       Amendment 
---  ----------------------  ------------------------------------ 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ------------------------------------------------------------ 
 a.   Name                    Redx Pharma Plc 
---  ----------------------  ------------------------------------ 
 b.   LEI                     213800HMS4EBXO589Y37 
---  ----------------------  ------------------------------------ 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ------------------------------------------------------------ 
 a.   Description             Options over Ordinary Shares of 
       of the financial        1p each 
       instrument, 
       type of instrument 
 
       Identification          ISIN: GB00BSNB6S51 
       Code 
---  ----------------------  ------------------------------------ 
 b.   Nature of the           Grant of options under the EMI 
       transaction             Share Scheme 
---  ----------------------  ------------------------------------ 
 c.   Price(s) and            Option awarded over 166,667 shares 
       volume(s)               at an exercise price of 22p per 
                               share 
 
                               Option awarded over 166,667 shares 
                               at an exercise price of 33p per 
                               share 
 
                               Option awarded over 166,666 shares 
                               at an exercise price of 50p per 
                               share 
---  ----------------------  ------------------------------------ 
 d.   Aggregated              N/A - Single Transaction 
       information 
       - Aggregated 
       Volume 
       - Price 
---  ----------------------  ------------------------------------ 
 e.   Date of the             21/12/17 
       transaction 
---  ----------------------  ------------------------------------ 
 f.   Place of the            Outside of trading venue 
       transaction 
---  ----------------------  ------------------------------------ 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUAVRRBNAUUUA

(END) Dow Jones Newswires

December 22, 2017 02:00 ET (07:00 GMT)